Table 4 Antibody seropositivity rates and mean serum antibody levels
| Â | Seroprevalence rate | Mean serum levels OD/CO | |||||
|---|---|---|---|---|---|---|---|
| Â | PCa | BPH | OR | 95% CI | PCa | BPH | p |
HPV 6 | 77 (24.1%) | 21 (20.8%) | 1.21 | 0.71-2.12 | 2.608 | 3.162 | 0.0964 |
HPV 11 | 40 (12.5%) | 15 (14.9%) | 0.82 | 0.44-1.60 | 2.554 | 2.259 | 0.9698 |
HPV 16 | 16 (5.0%) | 10 (9.9%) | 0.48 | 0.21-1.13 | 3.470 | 3.251 | 0.8743 |
HPV 18 | 8 (2.5%) | 10 (9.9%) | 0.23 | 0.09-0.61 | 1.496 | 1.365 | 0.9290 |
HPV 31 | 19 (5.9%) | 8 (7.9%) | 0.73 | 0.32-1.83 | 2.616 | 3.640 | 0.1053 |
HPV 33 | 7 (2.2%) | 5 (5.0%) | 0.43 | 0.13-1.48 | 2.156 | 3.620 | 0.3434 |
CMV | 264 (80.2%) | 91 (86.7%) | 0.62 | 0.32-1.14 | 3.839 | 4.407 | 0.0004 |
HSV 1 | 313 (95.1%) | 99 (94.3%) | 1.19 | 0.42-2.97 | 3.760 | 3.832 | 0.9649 |
HSV 2 | 42 (12.8%) | 14 (13.3%) | 0.95 | 0.51-1.88 | 5.362 | 4.859 | 0.8056 |
Chlamydia trachomatis | 18 (5.5%) | 12 (11.4%) | 0.45 | 0.21-0.99 | 1.281 | 1.210 | 0.6560 |
Mycoplasma hominis | 60 (18.2%) | 15 (14.3%) | 1.34 | 0.74-2.55 | NA | NA | - |
Ureaplasma urealyticum | 64 (19.5%) | 11 (10.5%) | 2.06 | 1.08-4.28 | NA | NA | - |
Neisseria gonorrhoeae | 20 (6.1%) | 6 (5.7%) | 1.07 | 0.44-2.99 | NA | NA | - |
Treponema pallidum | 1 (0.3%) | 0 (0%) | NA | NA | NA | NA | - |